

# South Dakota Department of Social Services, Division of Medicaid Services Pharmacy & Therapeutics (P&T) Committee Meeting Minutes

Friday, March 8, 2024

1:00 – 3:00 pm CT

## Members and DSS Staff

Michelle Baack, MD	X	Matthew Stanley, DO	X
Bill Ladwig, RPh	X	Deidra Van Gilder, PharmD, Chair	X
Kelley Oehlke, PharmD	X	Clarissa Barnes, MD, DSS Staff	X
Lenny Petrik, PharmD		Mike Jockheck, DSS Staff	X
Heather Preuss, MD	X	Taylor Koerner, DSS Staff	X

## Administrative Business

Van Gilder called the meeting to order at 1:02 pm. The minutes of the December meeting were presented. Baack made a motion to approve. Oehlke seconded the motion. The motion was unanimously approved.

## Prior Authorization Update (PA) and Statistics

The committee reviewed the PA activity report from October 1, 2023, to December 31, 2023. A total of 2,845 PAs were reviewed of which 173 requests (6.1%) were received via telephone, 131 requests (4.6%) were received via fax, 940 (33%) were reviewed electronically, and 1,594 (56%) were received via ePA. After a full year since ePA implementation, it continues to dominate. There was a 17.8% increase in PAs received compared to the previous quarter. The therapeutic class ADHD/Anti-narcolepsy debut on the Top Classes for PAs reviewed.

## Analysis of the Top 15 Therapeutic Classes and Drug Spend

The committee reviewed the top 15 therapeutic classes by total cost of claims from October 1, 2023, to December 31, 2023. The top five therapeutic classes based on paid amount were atypical antipsychotics, disease-modifying anti-rheumatic agents, skin and mucous membrane agents, incretin mimetics, and cystic fibrosis correctors. These top 15 therapeutic classes comprise 22.67% of total claims. The committee also reviewed the top 50 drugs based on amount paid and number of claims. The top 50 drugs by amount paid make up 8.36% of total claims.

## Old Business

### Seglentis & tramadol review

The committee reviewed the Seglentis utilization. Stanley commented that there is not a clinical benefit or reason to support a combination drug. Baack motioned to adopt PA similar to State B for prescribers to provide a letter necessity. Stanley seconded the motion. Van Gilder inquired if there was any public comment. There was none. The motion was approved unanimously.

### Hepatitis C review

The committee had inquired on the number of members that were not treated for hepatitis C since the PA criteria was changed. Based on the number of rejected claims and number treated, the state will investigate if the untreated members are still part of the current Medicaid population.

## **Opioid Update**

The committee reviewed 4Q2023 opioid outcomes compared to the previous quarter from the opioid initiatives. There was an increase in opioid utilization and utilizers during 4Q2023 with corresponding increase in total eligibility and utilizers. The committee also reviewed the average MME/day/utilizer graph. Ladwig and Baack were satisfied with the downward trend. Jockheck reviewed the hospitalization rates due to opioids, which has also dropped. Jockheck mentioned they were not able to provide deaths due to opioids because the cause of death is not always provided. The use of opioids at high dosage in person without cancer tracking showed a response rate decrease from 9.55% to 4.47%. Stanley expressed interest in reviewing MAT trends at the next meeting to determine if more opioid use disorder is being treated and to help determine the success of the opioid initiatives. Stanley stated guidelines from ACOG are clearer with education and better studies coming out to support interventions and the best ways to address it.

## **New Business**

### **PMPM comparison**

The committee reviewed the PMPM trend compared to other Medicaid states and managed Medicaid from the past year. Ladwig commented on the comparison of managed Medicaid PMPM which was higher than FFS Medicaid plans. Jockheck clarified the PMPM figures are not net of rebates.

### **Brand Inhalers review**

The strategy and potential savings of preferring brand inhalers over generics was presented to the committee. Ladwig mentioned all product availability changed as of January 1<sup>st</sup> which Jockheck concurred had been discussed internally. Preferring brand over generics could be an alternative strategy that the state may be utilizing to drive to the lowest net drug.

Van Gilder inquired if there was any public comment on agenda items covered thus far. There was none.

### **Glucose Test Strip Review**

The committee reviewed the glucose test strip utilization and discussed reducing the quantity limit for all members and for members using a CGM. After discussion, it was agreed to reduce the quantity to 150 per 30 days for members aged 6 years and older. For members newly diagnosed with diabetes to allow a quantity of 306 per 30 days for one year. For children under 5 years old and under, to allow a quantity of 306 per 30 days. Baack made the motion and Ladwig seconded it. Van Gilder inquired if there was any public comment. There was none. The motion was approved unanimously.

### **Zorvye**

Zorvye cream and foam clinical information was presented for review. After discussion, Van Gilder made the motion to apply the same criteria as Vtama with appropriate age and diagnosis for cream and foam with initial criteria for 6 months and reauthorization for 12 months. Ladwig seconded the motion. Van Gilder inquired if there was any public comment. There was none. The motion was approved unanimously.

### **Zurzuvae**

Zurzuvae clinical information was presented for review. Baack expressed concern on the drug's embryofetal toxicity and causing somnolence on breastfed infants. The appropriateness of a trial and failure of a SSRI was discussed. Stanley stated it would be wise to be cautious until there is more clinical experience with this drug. Van Gilder agreed drug should be used with caution when breastfeeding. Daphne Ni, Medical Liaison from Biogen, provided public comment. After discussion, the committee agreed with the

PA criteria for Zurzuvae. Baack motioned as discussed. Stanley seconded the motion. The motion was approved unanimously.

**Adjournment**

The next meeting is scheduled on June 7, 2024. The September meeting is scheduled for September 20, 2024. Van Gilder motioned to adjourn the meeting and Baack seconded the motion. The motion to adjourn the meeting was unanimous and the meeting adjourned at 2:58 pm CT.

DRAFT